Toyota Motor Corp. is planning to unwind about ¥3 trillion ($19 billion) of strategic shareholdings in a process that would see financial institutions sell the automaker’s shares, Reuters reported . The value of the sale may be higher, depending on the willingness of shareholders to sell, Reuters said, citing people familiar with the matter it didn’t identify. Toyota is aiming for the sale to happ...
Toyota Motor Corp. is planning to unwind about ¥3 trillion ($19 billion) of strategic shareholdings in a process that would see financial institutions sell the automaker’s shares, Reuters reported . The value of the sale may be higher, depending on the willingness of shareholders to sell, Reuters said, citing people familiar with the matter it didn’t identify. Toyota is aiming for the sale to happen as early as this year, though the timing and scale could change — or the plan could be abandoned altogether, it said. The carmaker began unwinding cross-held shares years ago in response to government reforms pushing large corporations to untangle strategic shares to boost investor returns and encourage fair competition. Toyota’s significance — it is Japan’s largest company and the centerpiece of the Toyota group — means a share sale of this size would be a significant boost to those reform efforts. The company had announced a ¥1.2 trillion share buyback program in 2024. Read more: Toyota Raises Buyback to ¥1.2 Trillion, Citing Share Levels
Hong Kong billionaire Victor Li ’s CK Group has agreed to sell the UK’s largest power-distribution network, as flagship conglomerate CK Hutchison Holdings Ltd. eyes asset divestments to reshape the business for a geopolitically fraught era. Unit CK Infrastructure Group said it expects an effective gain of about HK$14.5 billion ($1.9 billion) from transactions related to the £10.5 billion ($14.2 bi...
Hong Kong billionaire Victor Li ’s CK Group has agreed to sell the UK’s largest power-distribution network, as flagship conglomerate CK Hutchison Holdings Ltd. eyes asset divestments to reshape the business for a geopolitically fraught era. Unit CK Infrastructure Group said it expects an effective gain of about HK$14.5 billion ($1.9 billion) from transactions related to the £10.5 billion ($14.2 billion) sale of UK Power Networks to French utility Engie SA , according to a Thursday stock exchange filing. The proceeds will allow it to generate cash for future investments or acquisitions, the company said. CK Hutchison shares rose as much as 3.7% in Hong Kong, the most in three weeks. Read More: Li Ka-shing Is Remaking His Empire as a Generational Shift Looms The deal fits into a broader rethink of the storied company’s portfolio, which includes asset sales and potential spin-offs. The moves could ultimately reshape the empire founded by Li Ka-shing , whose emphasis on stable and predictable returns saw him build his fortune by investing in regulated infrastructure and telecom assets in developed Western markets. But Li’s elder son Victor, who has chaired the group since 2018, must now steer the company through a more volatile landscape marked by increasing trade tensions and the disruptive rise of artificial intelligence. “From a credit perspective, the deal is positive as it could improve CK Hutchison’s leverage by as much as 0.5x and gives the company firepower to pursue acquisitions,” said Bloomberg Intelligence credit analyst Sharon Chen . CK Hutchison is also considering listing its health and beauty retailer A.S. Watson Group , Bloomberg News reported in November. The power asset sales comes as CK Hutchison’s proposed sale of 43 global ports grows more complicated. Panama this week moved to occupy two of the company’s facilities near the Panama Canal, assets that have become a flashpoint in US-China tensions. Talks with a buyer consortium that includes US invest...
The average one-year price target for Brunello Cucinelli S.p.A. - Depositary Receipt (OTCPK:BCUCY) has been revised to $34.64 / share. This is a decrease of 21.71% from the prior estimate of $44.24 dated February 3, 2026. The price target is an average of many
The average one-year price target for Brunello Cucinelli S.p.A. - Depositary Receipt (OTCPK:BCUCY) has been revised to $34.64 / share. This is a decrease of 21.71% from the prior estimate of $44.24 dated February 3, 2026. The price target is an average of many
Earnings Call Insights: Veracyte (VCYT) Q4 2025 Management View Marc Stapley, CEO, reported "Q4 capped off another outstanding year of strong execution for Veracyte with performance across our core businesses that reinforces both the durability of our growth model and the opportunities ahead." He highlighted that total revenue for the fourth quarter was $141 million, up 19% year-over-year, driven ...
Earnings Call Insights: Veracyte (VCYT) Q4 2025 Management View Marc Stapley, CEO, reported "Q4 capped off another outstanding year of strong execution for Veracyte with performance across our core businesses that reinforces both the durability of our growth model and the opportunities ahead." He highlighted that total revenue for the fourth quarter was $141 million, up 19% year-over-year, driven by continued strength in the core testing business. Decipher volume grew 21% and Afirma grew 12%, resulting in a combined 16% total testing volume growth. Stapley noted the company provided clinically actionable information to nearly 170,000 patients in the year and has now served over 800,000 patients to date. He stated, "We remain on track to testing our 1 millionth patient later this year." Key 2025 milestones included launching Decipher for metastatic patients, expanding into advanced disease, and generating new clinical evidence across endocrinology and neurology. The pipeline advanced with positive Prosigna outcomes data from the OPTIMA PRELIM study, submission of a technical assessment for TrueMRD, and completion of enrollment for the NIGHTINGALE lung cancer study. Stapley emphasized, "Adjusted EBITDA margin exceeded 27% in 2025, not only reaching but surpassing our 25% target more than a year ahead of plan." Operational priorities included restructuring Veracyte SAS and transitioning all Afirma volume to the v2 transcriptome platform. Looking forward, Stapley described a phased expansion strategy: ongoing core business growth, two product launches in 2026 (TrueMRD for muscle invasive bladder cancer and Prosigna for early-stage breast cancer), and longer-term commitments including geographic expansion. Rebecca Chambers, CFO, stated, "Q4 was another exceptional quarter with $140.6 million in revenue, an increase of 19% over the prior year period." She added, "We grew total volume to approximately 48,000 tests, a 16% increase over the same period in 2024 and generated ...
According to an SEC filing dated Feb. 17, 2026, Palo Duro Investment Partners, LP initiated a new position in Darling Ingredients (NYSE:DAR) acquiring 632,050 shares during the fourth quarter. The estimated transaction value, based on the average closing price over the quarter, was approximately $22.75 million. The stake’s quarter-end value also stood at $22.75 million, reflecting both the size of...
According to an SEC filing dated Feb. 17, 2026, Palo Duro Investment Partners, LP initiated a new position in Darling Ingredients (NYSE:DAR) acquiring 632,050 shares during the fourth quarter. The estimated transaction value, based on the average closing price over the quarter, was approximately $22.75 million. The stake’s quarter-end value also stood at $22.75 million, reflecting both the size of the purchase and prevailing stock prices at the period’s close. This new holding represents 6.8% of the fund’s 13F reportable assets under management as of Dec. 31, 2025. As of Feb. 25, 2026, shares of Darling Ingredients were priced at $53.08, up 34.8% over the past year, outperforming the S&P 500 by 19 percentage points. Continue reading